This article is more than 5 years old. Information may no longer be current.

NCCN Foundation honors young investigators

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The NCCN Foundation this year has presented Young Investigator Awards to five researchers at National Comprehensive Cancer Network member institutions.

Honorees receive funding for a 2-year period. They also will have the opportunity to present their findings during the general poster session at an NCCN Annual Conference.

This year’s recipients are:

• Kemi Doll, MD, MSCR, of Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, whose research project is titled “Racial Disparities in Endometrial Cancer;”
• Saad Kenderian , MB, CHB, of Mayo Clinic, whose research project is titled “Chimeric Antigen Receptor T-Cell Therapy in Chronic Lymphocytic Leukemia: Mechanisms of Resistance and Strategies to Enhance Efficacy;”
• Florian Muller, PhD, of The University of Texas MD Anderson Cancer Center, whose research project is titled “ENO1-Deletion as a Target for Personalized Oncology: Collateral Lethality to the Clinic;”
• Elizabeth Stewart, MD, of St. Jude Children’s Research Hospital/University of Tennessee Health Science Center, whose research project is titled “Preclinical Match;” and
• Liqin Zhu, PhD, of St. Jude Children’s Research Hospital/University of Tennessee Health Science Center, whose research project is titled “Patient-Derived Tumor Spheroids for High-Risk Hepatoblastoma Drug Discovery.”